suramin

Summary

Summary: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.

Top Publications

  1. ncbi Differential properties of astrocyte calcium waves mediated by P2Y1 and P2Y2 receptors
    Conor J Gallagher
    Programme in Brain and Behaviour, Hospital for Sick Children, University of Toronto, Toronto, Ontario M5G 1X8, Canada
    J Neurosci 23:6728-39. 2003
  2. ncbi Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins)
    Johannes Trapp
    Institute of Pharmaceutical Sciences, Albert Ludwigs Universitat Freiburg, 79104 Freiburg, Germany
    ChemMedChem 2:1419-31. 2007
  3. ncbi Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin
    Anja Schuetz
    Structural Genomics Consortium, University of Toronto, 100 College Street, Toronto, Ontario M5G 1L5, Canada
    Structure 15:377-89. 2007
  4. ncbi Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication
    Max Nunziante
    Prion Research Group, Institute of Virology, Technical University of Munich, Biedersteiner Str 29, 80802 Munich, Germany
    J Cell Sci 118:4959-73. 2005
  5. pmc Diabetes-induced renal injury in rats is attenuated by suramin
    Midhun C Korrapati
    Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA
    J Pharmacol Exp Ther 343:34-43. 2012
  6. ncbi Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania
    S N Kibona
    National Institute for Medical Research, Tabora, Tanzania
    Trop Med Int Health 11:144-55. 2006
  7. ncbi ATP released via gap junction hemichannels from the pigment epithelium regulates neural retinal progenitor proliferation
    Rachael A Pearson
    Department of Physiology, University College London, Gower Street, London WC1E 6BT, United Kingdom
    Neuron 46:731-44. 2005
  8. ncbi Tissue protective and anti-fibrotic actions of suramin: new uses of an old drug
    Na Liu
    Department of Medicine, Rhode Island Hospital and Brown University School of Medicine, Providence, RI 02903, USA
    Curr Clin Pharmacol 6:137-42. 2011
  9. pmc Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop
    S El-Ajouz
    Department of Cell Physiology and Pharmacology, University of Leicester, Leicester, UK
    Br J Pharmacol 165:390-400. 2012
  10. ncbi Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin
    A G Scott
    Parasitology Laboratory, University of Glasgow, UK
    Acta Trop 60:251-62. 1996

Detail Information

Publications267 found, 100 shown here

  1. ncbi Differential properties of astrocyte calcium waves mediated by P2Y1 and P2Y2 receptors
    Conor J Gallagher
    Programme in Brain and Behaviour, Hospital for Sick Children, University of Toronto, Toronto, Ontario M5G 1X8, Canada
    J Neurosci 23:6728-39. 2003
    ..Thus, processes that alter expression or function of these receptors may control the rate and extent of astrocyte Ca2+ waves...
  2. ncbi Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins)
    Johannes Trapp
    Institute of Pharmaceutical Sciences, Albert Ludwigs Universitat Freiburg, 79104 Freiburg, Germany
    ChemMedChem 2:1419-31. 2007
    b>Suramin is a symmetric polyanionic naphthylurea originally used for the treatment of trypanosomiasis and onchocerciasis...
  3. ncbi Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin
    Anja Schuetz
    Structural Genomics Consortium, University of Toronto, 100 College Street, Toronto, Ontario M5G 1L5, Canada
    Structure 15:377-89. 2007
    ..We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity ..
  4. ncbi Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication
    Max Nunziante
    Prion Research Group, Institute of Virology, Technical University of Munich, Biedersteiner Str 29, 80802 Munich, Germany
    J Cell Sci 118:4959-73. 2005
    ..Among these, the drug suramin induces aggregation and re-targeting of PrPc to endocytic compartments...
  5. pmc Diabetes-induced renal injury in rats is attenuated by suramin
    Midhun C Korrapati
    Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA
    J Pharmacol Exp Ther 343:34-43. 2012
    ..We examined the efficacy and mechanism(s) of suramin on hyperglycemia-induced renal injury before development of overt histological damage...
  6. ncbi Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania
    S N Kibona
    National Institute for Medical Research, Tabora, Tanzania
    Trop Med Int Health 11:144-55. 2006
    ..To determine the drug resistance of Trypanosoma brucei rhodesiense strains isolated from sleeping sickness patients in Tanzania...
  7. ncbi ATP released via gap junction hemichannels from the pigment epithelium regulates neural retinal progenitor proliferation
    Rachael A Pearson
    Department of Physiology, University College London, Gower Street, London WC1E 6BT, United Kingdom
    Neuron 46:731-44. 2005
    ..ATP released from RPE hemichannels speeds both cell division and proliferation in the neural retina...
  8. ncbi Tissue protective and anti-fibrotic actions of suramin: new uses of an old drug
    Na Liu
    Department of Medicine, Rhode Island Hospital and Brown University School of Medicine, Providence, RI 02903, USA
    Curr Clin Pharmacol 6:137-42. 2011
    b>Suramin is a polysulfonated naphthylurea, which was originally synthesized and designed as a treatment for trypanosomiasis and selected malignancies and metastatic diseases...
  9. pmc Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop
    S El-Ajouz
    Department of Cell Physiology and Pharmacology, University of Leicester, Leicester, UK
    Br J Pharmacol 165:390-400. 2012
    ..In this study we have determined the contribution of the head region to the antagonist action of NF449 and suramin at the human P2X1 receptor.
  10. ncbi Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin
    A G Scott
    Parasitology Laboratory, University of Glasgow, UK
    Acta Trop 60:251-62. 1996
    ..lines expressing resistance to the melaminophenyl arsenical drug cymelarsan (247MelCyR and 386MelCyR) and to suramin (247SurR and 386SurR)...
  11. pmc Recovery from glycerol-induced acute kidney injury is accelerated by suramin
    Midhun C Korrapati
    Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, 280 Calhoun St, Charleston, SC 29425, USA
    J Pharmacol Exp Ther 341:126-36. 2012
    ..In this study, we examined the efficacy and mechanism(s) of suramin in promoting recovery from glycerol-induced AKI, a model of rhabdomyolysis-induced AKI...
  12. ncbi Effects of the P2-purinoceptor antagonists suramin and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid on glutamatergic synaptic transmission in rat dorsal horn neurons of the spinal cord
    J G Gu
    Department of Physiology and Cellular Biophysics and the Center for Neurobiology and Behavior, Columbia University, New York, NY 10032, USA
    Neurosci Lett 253:167-70. 1998
    The effects of suramin and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) on glutamatergic synaptic transmission were studied on dorsal horn lamina II neurons of rat spinal cord slice preparation and cultured dorsal horn ..
  13. ncbi Cloning, tissue distribution and functional characterization of the chicken P2X1 receptor
    Florentina Soto
    Department Molecular Biology of Neuronal Signals, Max Planck Institute for Experimental Medicine, Hermann Rein Str 3, D 37075, Gottingen, Germany
    FEBS Lett 533:54-8. 2003
    ..However, the antagonists suramin and NF023 were much less potent at chicken P2X1 receptors than at human P2X1 receptors...
  14. pmc Suramin inhibits renal fibrosis in chronic kidney disease
    Na Liu
    Department of Medicine, Rhode Island Hospital and Brown University School of Medicine, Providence, Rhode Island, USA
    J Am Soc Nephrol 22:1064-75. 2011
    ..b>Suramin is a compound that inhibits the interaction of several cytokines and growth factors with their receptors, but ..
  15. pmc Structural characterization of myotoxic ecarpholin S from Echis carinatus venom
    Xingding Zhou
    Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore 117543, Singapore
    Biophys J 95:3366-80. 2008
    ..The crystal structures of native ecarpholin S and its complexes with lauric acid, and its inhibitor suramin, were elucidated. This is the first report of the structure of a member of the Ser(49)-PLA(2) subgroup...
  16. ncbi Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-β1 blocker
    Ana Paula Tiemi Taniguti
    Departamento de Anatomia, Biologia Celular, Fisiologia e Biofísica, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, SãoPaulo 13083 970, Brazil
    Muscle Nerve 43:82-7. 2011
    ..We evaluated the effect of suramin, a transforming growth factor-beta 1 (TGF-β1) blocker, on fibrosis in mdx mice...
  17. pmc Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue
    E Fonfria
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Harlow, Essex, UK
    Br J Pharmacol 153:544-56. 2008
    ..The human, rat, and mouse P2X(7) receptors have been previously characterized, and in this study we report the cloning and pharmacological properties of the guinea pig orthologue...
  18. pmc Quantal release of ATP in mouse cortex
    Yuriy Pankratov
    Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, UK
    J Gen Physiol 129:257-65. 2007
    ..receptor (AMPA, kainate) antagonists; smaller events were partially inhibited by P2X receptor antagonists suramin and PPADS. The decay of the larger events was selectively prolonged by cyclothiazide...
  19. ncbi Suramin: clinical uses and structure-activity relationships
    Ross P McGeary
    School of Molecular and Microbial Sciences, The University of Queensland, Brisbane, QLD 4072, Australia
    Mini Rev Med Chem 8:1384-94. 2008
    b>Suramin is a polysulfonated polyaromatic symmetrical urea. It is currently used to treat African river blindness and African sleeping sickness...
  20. ncbi Divergent effects of the purinoceptor antagonists suramin and pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) (PPNDS) on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors
    Erika Suzuki
    Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, Illinois 62702, USA
    Mol Pharmacol 66:1738-47. 2004
    b>Suramin is a large naphthyl-polysulfonate compound that inhibits an array of receptors and enzymes, and it has also been reported to block currents mediated by glutamate receptors...
  21. ncbi Coexpression of rat P2X2 and P2X6 subunits in Xenopus oocytes
    B F King
    Autonomic Neuroscience Institute, Royal Free and University College Medical School, Royal Free Campus, Hampstead, London NW3 2PF, United Kingdom
    J Neurosci 20:4871-7. 2000
    ..Also, H(+) ions inhibited ATP responses at low pH levels (<pH 6.3). The pH-dependent blocking activity of suramin was changed at this heteromeric receptor, although the potentiating effect of Zn(2+) on ATP responses was ..
  22. ncbi Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking
    Christian Wolf
    Department of Molecular Pharmacology, RWTH Aachen University, Aachen, Germany
    Mol Pharmacol 79:649-61. 2011
    ..acid) tetrasodium salt (NF770) as a nanomolar-potent competitive P2X2 receptor antagonist within a series of 139 suramin derivatives...
  23. ncbi The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury
    Yi Sheng Chan
    Department of Orthopaedic Surgery, University of Pittsburgh, Pennsylvania 15213, USA
    Am J Sports Med 33:43-51. 2005
    ..Muscle strain injuries are extremely common in sports medicine. Muscle healing often is hindered by scar tissue formation after injury...
  24. pmc Regulation of the calcium release channel from skeletal muscle by suramin and the disulfonated stilbene derivatives DIDS, DBDS, and DNDS
    Erin R O'Neill
    School of Biomedical Sciences, Faculty of Health, The University of Newcastle, Callaghan, New South Wales 2308, Australia
    Biophys J 84:1674-89. 2003
    Activation of skeletal muscle ryanodine receptors (RyRs) by suramin and disulfonic stilbene derivatives (Diisothiocyanostilbene-2',2'-disulfonic acid (DIDS), 4,4'-dibenzamidostilbene-2,2'-disulfonic acid (DBDS),and 4,4'-dinitrostilbene-2,..
  25. ncbi The entry of ivermectin and suramin into Onchocerca ochengi nodules
    H F Cross
    Liverpool School of Tropical Medicine, U K
    Ann Trop Med Parasitol 91:393-401. 1997
    ..if this was the problem, the distributions of the microfilaricide, ivermectin, and the partial macrofilaricide, suramin, in plasma, skin, nodule capsules and nodule contents were determined in cattle naturally infected with O...
  26. ncbi Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin
    Mario T Murakami
    Departament of Physics, IBILCE UNESP, Sao Jose do Rio Preto, SP, Brazil
    J Mol Biol 350:416-26. 2005
    b>Suramin, a synthetic polysulfonated compound, developed initially for the treatment of African trypanosomiasis and onchocerciasis, is currently used for the treatment of several medically relevant disorders...
  27. ncbi Mitogen-activated protein kinase signaling is involved in suramin-induced neurite outgrowth in a neuronal cell line
    Hiroyasu Nakata
    Department of Molecular Cell Signaling, Tokyo Metropolitan Institute for Neuroscience, Fuchu, Tokyo 183 8526, Japan
    Biochem Biophys Res Commun 355:842-8. 2007
    b>Suramin is a well-known antitrypanosomal drug and a novel experimental agent for the treatment of several cancers...
  28. ncbi Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice
    Sören T Eichhorst
    Ludwig Maximilians University Munich, University Hospital Grosshadern, Department of Internal Medicine II, Marchioninistrasse 15, D 81377 Munich, Germany
    Nat Med 10:602-9. 2004
    b>Suramin is a polysulfonated derivative of urea and has been widely used both to treat infections and as a chemotherapeutic drug...
  29. pmc The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats
    Mohamed Izikki
    INSERM U999, Le Plessis Robinson, France
    PLoS ONE 8:e77073. 2013
    ..All these receptors belong to the receptor tyrosine kinase (RTK) family...
  30. ncbi Suramin inhibits the in vitro expression of encephalitis B virus proteins NS3 and E
    Keshu Xu
    Department of Gastroenterology, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022
    J Huazhong Univ Sci Technolog Med Sci 23:375-9. 2003
    In this study, the mechanism by which Suramin inhibits the replication of epidemic encephalitis B virus was explored to provide a theoretical basis for its further application in clinical practice...
  31. ncbi The growth factor inhibitor suramin reduces apoptosis and cell aggregation in protein-free CHO cell batch cultures
    J A Zanghi
    Institute of Biotechnology, Swiss Federal Institute of Technology, ETH Honggerberg, HPT, CH 8093 Zurich, Switzerland
    Biotechnol Prog 16:319-25. 2000
    ..in apoptosis under these conditions, we examined the effect of the growth factor inhibitor and antitumor agent suramin on CHO cell growth and apoptosis in serum-free culture...
  32. ncbi Suramin and minocycline treatment of experimental African trypanososmiasis at an early stage of parasite brain invasion
    Daniel Ndem Amin
    Department of Neuroscience, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Acta Trop 106:72-4. 2008
    ..Three daily intraperitoneal injections of 20mg/kg suramin starting at 15 days post-infection (p.i...
  33. ncbi Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-kappaB activity
    Takashi Goto
    Department of Gastroenterology, Akita University School of Medicine, 1 1 1 Hondo, Akita 010 8543, Japan
    Cytokine 33:28-35. 2006
    b>Suramin is a symmetrical polysulfonated naphthylamine derivative of urea. There have been few studies on the effect of suramin on cytokines. We examined the effects of suramin on production of inflammatory cytokines.
  34. ncbi Suramin-induced reciprocal changes in glucose and lactate synthesis in renal tubules contribute to its hyperglycaemic action
    Adam K Jagielski
    Department of Metabolic Regulation, Institute of Biochemistry, Warsaw University, I Miecznikowa 1, 02 096 Warsaw, Poland
    Eur J Pharmacol 537:205-9. 2006
    b>Suramin is the drug of choice for the treatment of African trypanosomiasis and onchocerciasis. It is also tested for its potential use as an anticancer agent and chemosensitizer...
  35. pmc Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane
    R Danesi
    Scuola Superiore di Studi Universitari e di Perfezionamento S Anna, Pisa, Italy
    Br J Cancer 68:932-8. 1993
    The effects of suramin, an inhibitor of growth factor mitogenic activity, were evaluated on basic fibroblast growth factor (bFGF)-induced proliferation of bovine aortic endothelial cells and on angiogenesis in the chorioallantoic ..
  36. pmc Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes
    Maryam B Lustberg
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, B421 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210 1240, USA
    Cancer Chemother Pharmacol 70:49-56. 2012
    b>Suramin, a polysulfonated naphthylurea, inhibits the actions of polypeptide growth factors including acidic and basic fibroblast growth factors (aFGF and bFGF), which confer broad spectrum chemotherapy resistance...
  37. ncbi Ultraviolet-B activates components of the systemin signaling pathway in Lycopersicon peruvianum suspension-cultured cells
    Roopa Devi Yalamanchili
    Institution Department of Biological Sciences, University of South Carolina, Columbia, South Carolina 29208, USA
    J Biol Chem 277:28424-30. 2002
    ..Here, we report that both responses are induced in the cells by exposure to ultraviolet-B (UV-B) radiation. Suramin, an inhibitor of systemin receptor function, strongly inhibited the UV-B-induced medium alkalinization and MAPK ..
  38. pmc Functional characterization of intracellular Dictyostelium discoideum P2X receptors
    Melanie J Ludlow
    Department of Cell Physiology and Pharmacology, University of Leicester, Leicester LE1 9HN, United Kingdom
    J Biol Chem 284:35227-39. 2009
    ..insensitive to copper and the P2 receptor antagonists pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and suramin. Unusual for P2X channels, dP2XA and dP2XB were also Cl(-)-permeable...
  39. pmc Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis
    Changyong Li
    Department of Cell Biology, Municipal Laboratory for Liver Protection and Regulation of Regeneration, Capital Medical University, Beijing, China
    Am J Pathol 175:1464-72. 2009
    ..Furthermore, a selective S1P(3) receptor antagonist, suramin, markedly reduced the number of BM-derived cells during cholestasis...
  40. ncbi Inhibition of proteinase 3 (PR3) by suramin and fetal calf serum (FCS): effect of PR3 and suramin on Chinese hamster ovary cells (CHO-cells)
    Gholamreza Asadi Karam
    Department of Biochemistry, Faculty of Medicine, Rafsanjan Medical University, Post code 7719617996, Rafsanjan, Iran
    Pak J Pharm Sci 18:46-8. 2005
    ..A number of inhibitors for this proteinase are reported. Comprehensive studies on the inhibitory effect of suramin and heat treated fetal calf serum (deltaFCS) on PR3 have not been reported...
  41. ncbi Suramin promotes recovery from renal ischemia/reperfusion injury in mice
    Shougang Zhuang
    Department of Medicine, Brown University School of Medicine, Providence, Rhode Island, USA
    Kidney Int 75:304-11. 2009
    b>Suramin is a polysulfonated naphthylurea originally designed as a treatment for trypanosomiasis; but that has also been used to treat rodent models of fulminant hepatic failure and focal brain ischemia...
  42. ncbi Alteration of cholinergic, purinergic and sensory neurotransmission in the mouse colon of food allergy model
    Yuxin Leng
    Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, University of Toyama, Toyama 930 0194, Japan
    Neurosci Lett 445:195-8. 2008
    ..2%). Pretreatment with P2 purinoceptor antagonists [suramin and PPADs] significantly (P < 0.01) reduced the ATP-evoked contractions to 7.7% and 1...
  43. pmc Structure of severe fever with thrombocytopenia syndrome virus nucleocapsid protein in complex with suramin reveals therapeutic potential
    Lianying Jiao
    National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
    J Virol 87:6829-39. 2013
    ..In the screening of inhibitors Suramin was identified to bind phleboviral N specifically...
  44. ncbi Differentiation induction of mouse embryonic stem cells into sinus node-like cells by suramin
    Cornelia Wiese
    In Vitro Differentiation Group, Leibniz Institute of Plant Genetics and Crop Plant Research IPK, Corrensstrasse 3, D 06466 Gatersleben, Germany
    Int J Cardiol 147:95-111. 2011
    ..By using the naphthylamine derivative of urea, suramin, we were able to follow the process of cardiac specialization into sinus node-like cells.
  45. ncbi Suramin disrupts receptor-G protein coupling by blocking association of G protein alpha and betagamma subunits
    Wen Cheng Chung
    Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216 4505, USA
    J Pharmacol Exp Ther 313:191-8. 2005
    ..b>Suramin is considered a lead compound targeting this moiety...
  46. ncbi Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen
    Frank W Jennings
    Department of Veterinary Clinical Studies, University of Glasgow Veterinary School, Bearsden Road, Glasgow G61 1QH, Scotland, UK
    Parasitol Int 51:381-8. 2002
    ..The regimen commonly prescribed to treat CNS-stage disease involves the use of the trypanocidal drugs suramin and melarsoprol...
  47. ncbi Timing of the administration of suramin treatment after muscle injury
    Masahiro Nozaki
    Stem Cell Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Muscle Nerve 46:70-9. 2012
    It has been reported that suramin treatment can improve muscle healing; however, details about optimizing the dosing requirements remain unclear...
  48. ncbi Lysyl oxidase (LOX) mRNA expression and genes of the differentiated osteoblastic phenotype are upregulated in human osteosarcoma cells by suramin
    B Buchinger
    Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 4th Medical Department, Hanusch Hospital, Heinrich Collinstrasse 30, 1140 Vienna, Austria
    Cancer Lett 265:45-54. 2008
    It is well known that suramin influences proliferation and differentiation of tumour cells...
  49. ncbi Placental dysfunction in Suramin-treated rats: impact of maternal diabetes and effects of antioxidative treatment
    Peppi Nash
    Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
    J Soc Gynecol Investig 12:174-84. 2005
    ..The aim of the present study was to evaluate a rat model of placental dysfunction/preeclampsia in pregnancies complicated by maternal diabetes. A second objective was to evaluate the effects of vitamin E treatment in this model...
  50. ncbi Suramin counteracts the haemostatic disturbances produced by Bothrops jararaca snake venom
    Renato S Fernandes
    Instituto de Bioquimica Medica, Programa de Biologia Estrutural, Centro de Ciencias da Saude, Cidado Universitária, Universidade Federal do Rio de Janeiro, Ilha do Fundao, Rio de Janeiro, RJ, Brazil
    Toxicon 49:931-8. 2007
    ..b>Suramin is a hexasulfonated naphthylurea derivative that was recently characterized as a thrombin inhibitor (Monteiro et ..
  51. ncbi Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons
    J S Gill
    Molecular Neuroscience Program and Mayo Cancer Center, Mayo Clinic and Mayo Foundation, 1501 Guggenheim Building, 200 First Street SW, Rochester, Maine 55905
    Cell Death Differ 5:876-83. 1998
    b>Suramin is an experimental antineoplastic agent that is currently being tested in clinical trials for a number of human cancers...
  52. ncbi Suramin to enhance glaucoma filtering procedures: a clinical comparison with mitomycin
    H Mietz
    Department of Ophthalmology, University of Cologne, Koeln, Germany
    Ophthalmic Surg Lasers 32:358-69. 2001
    ..We performed a novel approach to enhance the outcome of trabeculectomies using suramin, a substance that inhibits the action of growth factors.
  53. ncbi Suramin blocks growth-stimulatory effects of platelet-derived growth factor on malignant fibrous histiocytomas in vitro
    A Abdiu
    Department of Biomedicine and Surgery, Faculty of Health Sciences, University of Linkoping, Sweden
    Cancer Lett 146:189-94. 1999
    The pattern of susceptibility of malignant cells to the cytostatic drug suramin is not fully clarified...
  54. ncbi Suramin-induced neuropathy in an animal model
    J W Russell
    University of Michigan, Department of Neurology, 4414 Kresge III, 200 Zina Pitcher Place, Ann Arbor, MI 48109 0588, USA
    J Neurol Sci 192:71-80. 2001
    b>Suramin is being used either alone, or in combination with other chemotherapeutic agents, in the treatment of hormone-refractory or metastatic prostate cancer...
  55. ncbi Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin. Implications for the mechanism of autocrine transformation
    S S Huang
    E A Doisy Department of Biochemistry, St Louis University School of Medicine, Missouri 63104
    J Biol Chem 263:12608-18. 1988
    ..to the cell-surface receptor, did not affect the rapid turnover of the PDGF receptor in sis-transformed cells; 4) suramin, an inhibitor for PDGF or v-sis gene product binding to the PDGF receptor, not only reversed the rapid turnover ..
  56. pmc Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy
    Na Liu
    Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
    J Pharmacol Exp Ther 338:758-66. 2011
    We recently showed that suramin treatment prevents the onset of renal fibrosis in a model of obstructive nephropathy induced by unilateral ureteral obstruction (UUO)...
  57. ncbi Paclitaxel and suramin-loaded core/shell microspheres in the treatment of brain tumors
    Hemin Nie
    Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore
    Biomaterials 31:8732-40. 2010
    ..Moreover, the release rates and characteristic sequences of multi-drugs can be tailored and tuned according to treatment necessity and applied in treating other kinds of tumors...
  58. ncbi Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro
    K Trieb
    Department of Orthopedics, University of Vienna, Währingergürtel 18 20, Vienna 1090, Austria
    Int J Biochem Cell Biol 35:1066-70. 2003
    ..b>Suramin has in the last two decades been used as salvage therapy in some cancers...
  59. ncbi Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein
    Vannakambadi K Ganesh
    Center for Biophysical Sciences and Engineering, University of Alabama at Birmingham, Birmingham, Alabama 35294 4400, USA
    Biochemistry 44:10757-65. 2005
    b>Suramin is a competitive inhibitor of heparin binding to many proteins, including viral envelope proteins, protein tyrosine phosphatases, and fibroblast growth factors (FGFs)...
  60. ncbi Suramin inhibits spinal cord microglia activation and long-term hyperalgesia induced by formalin injection
    Ying Wu
    Dental Research Center, School of Dentistry, University of North Carolina, Chapel Hill, North Carolina, USA
    J Pain 5:48-55. 2004
    ..The present study examined whether intrathecal delivery of suramin (a P2 receptor antagonist) blocks microglia activation and long-term hyperalgesia induced by formalin injection...
  61. ncbi Crystallization and preliminary X-ray diffraction analysis of suramin, a highly charged polysulfonated napthylurea, complexed with a myotoxic PLA2 from Bothrops asper venom
    Mario T Murakami
    Departamento de Fisica, IBILCE, Universidade Estadual Paulista, Cristóvão Colombo, 2265, Nazareth, 15054 000, Sao Jose do Rio Preto, SP, Brazil
    Biochim Biophys Acta 1703:83-5. 2004
    b>Suramin is a highly charged polysulfonated napthylurea that interferes in a number of physiologically relevant processes such as myotoxicity, blood coagulation and several kinds of cancers...
  62. ncbi Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer
    Mohammad Reza Safarinejad
    Department of Urology, Urology Nephrology Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
    Urol Oncol 23:93-101. 2005
    To investigate more effective chemotherapy against hormone refractory prostate cancer (HRPC) with the combination of estramustine (EM), docetaxel, and suramin.
  63. pmc The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site
    Hugh P Morgan
    Structural Biochemistry Group, Institute of Structural and Molecular Biology, University of Edinburgh, King s Buildings, Mayfield Road, Edinburgh EH9 3JR, Scotland, United Kingdom
    J Biol Chem 286:31232-40. 2011
    ..The molecular structures of the dyes provided a starting point for the synthesis of suramin, which was developed and used as a trypanocidal drug in 1916 and is still in clinical use...
  64. ncbi The NMR solution structure of human epidermal growth factor (hEGF) at physiological pH and its interactions with suramin
    Hsiao Wen Huang
    Department of Chemistry, National Tsing Hua University, Taiwan, ROC
    Biochem Biophys Res Commun 402:705-10. 2010
    ..b>Suramin, a polysulfonated naphthylurea that acts as a growth factor blocker, exhibits antiproliferative activity against ..
  65. ncbi Suramin promotes proliferation and scattering of renal epithelial cells
    Shougang Zhuang
    Department of Pharmaceutical Sciences, Medical University of South Carolina, 280 Calhoun Street, Charleston, SC 29425, USA
    J Pharmacol Exp Ther 314:383-90. 2005
    ..In this study, we show that suramin, a polysulfonated naphthylurea, stimulates outgrowth, scattering, and proliferation of primary cultures of renal ..
  66. ncbi Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors
    F Soto
    Max Planck Institute for Experimental Medicine, Gottingen, Germany
    Neuropharmacology 38:141-9. 1999
    The suramin analogue 8,8'-(carbonylbis(imino-3,1-phenylene carbonylimino)bis(1,3,5-naphthalenetrisulfonic acid) (NF023) antagonizes in a competitive fashion P2X receptor-mediated responses in certain vascular and visceral smooth muscles...
  67. ncbi Differential effects of suramin on protein kinase C isoenzymes. A novel tool for discriminating protein kinase C activities
    M Gschwendt
    Division of Tumor Cell Regulation, German Cancer Research Center, Heidelberg
    FEBS Lett 421:165-8. 1998
    b>Suramin, a hexasulfonated naphthylurea, is known to induce differentiation and inhibit proliferation, angiogenesis, and development of tumors...
  68. ncbi Suramin interaction with human alpha-thrombin: inhibitory effects and binding studies
    Robson Q Monteiro
    Departamento de Bioquimica Medica, ICB CCS, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
    Int J Biochem Cell Biol 36:2077-85. 2004
    b>Suramin is a hexasulfonated naphthylurea commonly used as antitrypanosomial drug and more recently for the treatment of malignant tumors...
  69. ncbi Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis
    Andrew Jonathan Nok
    Department of Biochemistry, Ahmadu Bello University, Zaria, Nigeria
    Parasitol Res 90:71-9. 2003
    ..So far the treatment for the early stage of HAT involves the drugs pentamidine and suramin which have been very successful...
  70. pmc A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP
    Feng Qiu
    Dept of Physiology and Biophysics, Univ of Miami School of Medicine, PO Box 016430, Miami, FL 33101, USA
    Am J Physiol Cell Physiol 296:C250-5. 2009
    ..ATP analogues, including benzoylbenzoyl-ATP, suramin, and brilliant blue G were even more effective inhibitors of pannexin 1 currents than ATP...
  71. ncbi The polysulfonated compound suramin blocks adsorption and lateral difusion of herpes simplex virus type-1 in vero cells
    J S Aguilar
    Department of Molecular Biology and Biochemistry and Program in Animal Virology, University of California, Irvine, Irvine, California, 92697, USA
    Virology 258:141-51. 1999
    ..We analyzed the actions of the polysulfonate compound suramin on the replication of herpes simplex virus type 1 (HSV-1) and compared them with the actions of heparin...
  72. ncbi Placental dysfunction in Suramin-treated rats--a new model for pre-eclampsia
    P Nash
    Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
    Placenta 26:410-8. 2005
    ..This study was carried out to evaluate if inhibited angiogenesis by Suramin injections in early pregnancy may cause a condition resembling pre-eclampsia in rats...
  73. ncbi Antagonism of myotoxic and paralyzing activities of bothropstoxin-I by suramin
    Maristela de Oliveira
    Departamento de Farmacologia, Instituto de Biociencias, Universidade Estadual Paulista, Rubiao Junior, Botucatu, CEP 18618 000 Sao Paulo, Brazil
    Toxicon 42:373-9. 2003
    ..In this work, we evaluated the ability of suramin, a polysulfonated naphtylurea derivative, to antagonize the myotoxic and the paralyzing activities of BthTX-I on ..
  74. ncbi The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range
    Susanne Horner
    Department of Pharmacology, University of Frankfurt, Marie Curie Strasse 9, 60439, Frankfurt Main, Germany
    Naunyn Schmiedebergs Arch Pharmacol 372:1-13. 2005
    ..means of selectively inhibiting platelet P2X1 receptors have been described, although recent work has shown that suramin is a useful lead compound for the development of high-affinity P2X1 antagonists...
  75. ncbi Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist
    Jürgen Rettinger
    Department of Molecular Pharmacology, Medical School of the Technical University of Aachen, Wendlingweg 2, D 52074 Aachen, Germany
    Neuropharmacology 48:461-8. 2005
    ..Based on suramin as a lead compound, several derivates have been described that block recombinant P2X receptors with orders of ..
  76. pmc Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior
    Edward W Inscho
    Department of Physiology, Medical College of Georgia, 1120 15th Street, Augusta, Georgia 30912 3000, USA
    J Clin Invest 112:1895-905. 2003
    ..These data provide compelling new evidence indicating that tubuloglomerular feedback signals are coupled to autoregulatory preglomerular vasoconstriction through ATP-mediated activation of P2X1 receptors...
  77. ncbi Effect of suramin on trypomastigote forms of Trypanosoma cruzi: changes on cell motility and on the ultrastructure of the flagellum-cell body attachment region
    Danielle F R Bisaggio
    Instituto de Microbiologia Professor Paulo de Goes, CCS, Bloco I, Universidade Federal do Rio de Janeiro, Ilha do Fundao, CEP 21941 590, Rio de Janeiro, RJ, Brazil
    Acta Trop 98:162-75. 2006
    b>Suramin has been previously reported to inhibit distinct cell enzymes and to affect the synthesis and distribution of cytoskeleton proteins...
  78. ncbi Thr339-to-serine substitution in rat P2X2 receptor second transmembrane domain causes constitutive opening and indicates a gating role for Lys308
    Lishuang Cao
    Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, United Kingdom
    J Neurosci 27:12916-23. 2007
    ..b>Suramin, which is a noncompetitive antagonist at wild-type P2X2 receptors, had a pronounced agonist action at both P2X2[..
  79. ncbi The effect of subconjunctival suramin on corneal neovascularization in rabbits
    Hyun Soo Lee
    Laboratory of Visual Science, St Mary s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Cornea 29:86-92. 2010
    To evaluate the effect of subconjunctival injection of suramin on corneal neovascularization in rabbits.
  80. ncbi Improved muscle healing after contusion injury by the inhibitory effect of suramin on myostatin, a negative regulator of muscle growth
    Masahiro Nozaki
    Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Am J Sports Med 36:2354-62. 2008
    ..Muscle contusions are the most common muscle injuries in sports medicine. Although these injuries are capable of healing, incomplete functional recovery often occurs...
  81. ncbi Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors
    Y Zhang
    College of Pharmacy and James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus 43210, USA
    J Pharmacol Exp Ther 299:426-33. 2001
    ..b>Suramin had no effect on the doxorubicin activity in the absence of CM or FGF, but reversed the CM- and FGF-induced ..
  82. ncbi Inhibition of receptor/G protein coupling by suramin analogues
    W Beindl
    Institute of Pharmacology, Vienna University, Austria
    Mol Pharmacol 50:415-23. 1996
    b>Suramin analogues act as direct antagonists of heterotrimeric G proteins because they block the rate-limiting step of G protein activation (i.e., the dissociation of GDP prebound to the G protein alpha subunit)...
  83. ncbi Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models
    Judith W Cook
    Section of Thoracic Surgery, Division of Cardiothoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Lung Cancer 42:263-74. 2003
    Surgical debulking of malignant mesothelioma (MM) ultimately fails due to local recurrence. Suramin, an inhibitor of extracellular growth factors (ECGFs), has demonstrated efficacy in the treatment of malignant mesothelioma in a small ..
  84. ncbi Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues
    Dario Marchetti
    Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
    Int J Cancer 104:167-74. 2003
    ..Heparanase activity correlates with the metastatic propensity of tumor cells. Suramin, a polysulfonated naphthylurea, is an inhibitor of heparanase with suramin analogues shown to possess ..
  85. ncbi The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor
    J Rettinger
    Department of Pharmacology, Biocentre Niederursel, University of Frankfurt, Marie Curie Strasse 9, D 60439 Frankfurt M, Germany
    Neuropharmacology 39:2044-53. 2000
    The suramin analogue 8,8'-(carbonylbis(imino-4, 1-phenylenecarbonylimino-4,1-phenylenecarbonylimino)) bis(1,3,5-naphthalenetrisul fonic acid) (NF279) was analysed with respect to its potency and P2X receptor subtype selectivity...
  86. ncbi Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist
    Matthias U Kassack
    Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany
    Eur J Med Chem 39:345-57. 2004
    ..5). In conclusion, NF449 remains the most potent and selective P2X(1) antagonist known. Potential lead compounds among the suramin class for P2X(3) (16d) and P2Y(1) (16a) receptors were identified.
  87. ncbi Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs
    M Hohenegger
    Institute of Pharmacology, University of Vienna, Austria
    Mol Pharmacol 50:1443-53. 1996
    Ca2+ release from skeletal muscle sarcoplasmic reticulum is activated by adenine nucleotides and suramin. Because suramin is known to interact with ATP-binding enzymes and ATP receptors (P2-purinergic receptors), the stimulation by ..
  88. pmc Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice
    Lisa Sanderson
    King s College London, Pharmaceutical Sciences Research Division, Guy s Campus, Hodgkin Building, London Bridge, London SE1 1UL, United Kingdom
    Antimicrob Agents Chemother 51:3136-46. 2007
    ..situ brain perfusion and isolated incubated choroid plexus techniques, we investigated the distribution of [(3)H]suramin into the central nervous systems (CNSs) of male BALB/c, FVB (wild-type), and P-glycoprotein-deficient (Mdr1a/..
  89. pmc Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease
    S Gilch
    Gene Center Munich, Max von Pettenkofer-Institute for Virology, Ludwig-Maximilians-University of Munich, Feodor-Lynen-Strasse 25, D-81377 Munich, Germany
    EMBO J 20:3957-66. 2001
    ..We show that the chemical compound Suramin induced aggregation of PrP in a post-ER/Golgi compartment and prevented further trafficking of PrP(c) to the ..
  90. ncbi Suramin's development: what did we learn?
    Maninderjeet Kaur
    Molecular Pharmacology Section, Cancer Therapeutic Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    Invest New Drugs 20:209-19. 2002
    b>Suramin, a polysulphonated napthylurea, has been extensively evaluated over the past 10 years as an anticancer agent, with the most interest in the treatment of prostate cancer...
  91. pmc Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin
    C De Giovanni
    Istituto di Cancerologia, , Italy
    Br J Cancer 72:1224-9. 1995
    ..b>Suramin, a drug which non-selectively interferes with the binding of growth factors to their cellular receptors, was used ..
  92. ncbi Antifibrotic effects of suramin in injured skeletal muscle after laceration
    Yi Sheng Chan
    Department of Orthopaedic Surgery, Children s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA 15213 2583, USA
    J Appl Physiol 95:771-80. 2003
    ..Our studies have shown that decreased fibrosis could improve muscle healing. Suramin has been found to inhibit transforming growth factor (TGF)-beta1 expression by competitively binding to the ..
  93. ncbi Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation
    Ajit Regmi
    Lilly Research Labs, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bone 36:284-91. 2005
    b>Suramin is a naphthalene trisulfonic acid derivative that inhibits osteoclast differentiation and bone resorption in vitro and in vivo; however, the mechanisms underlying this activity have not been studied...
  94. pmc An antagonist-insensitive P2X receptor expressed in epithelia and brain
    G Buell
    Glaxo Institute for Molecular Biology, Plan les Ouates, 1228 Geneva, Switzerland
    EMBO J 15:55-62. 1996
    ..They also introduce a new phenotype for ATP responses at P2X receptors--insensitivity to currently known antagonists...
  95. ncbi Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma
    Pooja Dua
    Gude Lab, Cancer Research Institute, Advanced Centre for Treatment Research and Education in Cancer ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India
    Int J Cancer 121:1600-8. 2007
    ..We hypothesized that suramin when combined with PTX enhances its antineoplastic effects, which we have examined using the B16F10 mouse ..
  96. ncbi Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists
    Günter Lambrecht
    Department of Pharmacology, Biocentre Niederursel, University of Frankfurt, Marie Curie Strasse 9, D 60439 Frankfurt Main, Germany
    Curr Pharm Des 8:2371-99. 2002
    ..recently been described which to some degree are more potent and more selective than earlier antagonists like suramin or pyridoxal-5'-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS)...
  97. ncbi ATP receptor-mediated synaptic currents in the central nervous system
    F A Edwards
    Department of Pharmacology, University College London, UK
    Nature 359:144-7. 1992
    ..of glutamate, gamma-aminobutyric acid or acetylcholine receptors but were blocked by the ATP receptor-blocker, suramin and the desensitizing ATP receptor-agonist alpha,beta-methylene-ATP...
  98. ncbi Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C
    Yan Xin
    College of Pharmacy, James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, Ohio, USA
    J Urol 174:322-7. 2005
    ..growth factors expressed in solid tumors induce broad-spectrum chemoresistance and their nonspecific inhibitor suramin (Sigma Chemical Co., St...
  99. pmc Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
    J J Ord
    Department of Urology, Churchill Hospital, Oxford, UK
    Br J Cancer 92:2140-7. 2005
    b>Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects...
  100. ncbi Megazol combined with suramin improves a new diagnosis index of the early meningo-encephalitic phase of experimental African trypanosomiasis
    Annabelle Darsaud
    Centre de Recherches du Service de Sante des Armees, La Tronche, France
    Trop Med Int Health 9:83-91. 2004
    ..alone at optimal doses does not cure late-stage disease tested in mouse models, however the combination of suramin and megazol is able to cure infected mice without CNS involvement...
  101. ncbi Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer
    Kimberly R Kalli
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Gynecol Oncol 94:705-12. 2004
    ..The role of estrogen and epidermal growth factor (EGF) in control of cell growth was investigated in a panel of ovarian carcinoma lines...

Research Grants62

  1. Chemoresistance in Renal Cell Cancer
    JESSIE AU; Fiscal Year: 2006
    ..Inhibitors of these FGF, including the monoclonal antibodies and suramin (at low concentrations with no cytotoxicity), completely reverse the FGF-induced resistance and enhance the ..
  2. Intra-bladder MMC &suramin for nonmuscle-invading &locally advanced bladder ca
    Ze Lu; Fiscal Year: 2012
    ..an alternative administration route: intra-bladder injection of controlled release formulations (CRF) of MMC and suramin, such that therapeutic active drug levels are delivered to deeper tissues...
  3. Metabolite effects on Group III and IV afferents
    MARC PETER KAUFMAN; Fiscal Year: 2013
    ..Likewise, the responses of the afferents to ATP will be blocked by PPADS and suramin [and those to bradykinin will be blocked by HOE-140]...
  4. Targeting DUSP-5 to Treat Vascular Anomalies
    Ramani Ramchandran; Fiscal Year: 2013
    ..Small molecules such as SM1842, FDA-approved compounds (Suramin), and SM1842 analogs can reverse this effect, thereby permitting a switch between WT and S147P function both at ..
  5. SAR OF NOVEL TOPO I INHIBITOR AGAINST PROSTATE CANCER
    YUE WEI LEE; Fiscal Year: 2001
    ..chemotherapeutic agents have proven ineffective against metastatic prostate cancer, with only estramustine, suramin, and mitoxanthrone showing low levels of efficacy...
  6. Sphingosine 1 Phosphate and Embolic Stroke
    Christian Waeber; Fiscal Year: 2003
    ..This will first be achieved by blocking Edg-3 receptors with suramin and by inhibiting Rho kinases with Y-27632...
  7. IN VITRO CORRELATIONS OF SURAMIN RESPONSE IN MELANOMA
    Charles Taylor; Fiscal Year: 1991
    b>Suramin is a polyanionic napthylurea used since the 1920s as an anti-parasitic agent. Recently, suramin was found to have antiretroviral and antitumor activities...
  8. DENGUE VIRUS INTERACTION WITH TARGET CELL RECEPTORS
    Rory Marks; Fiscal Year: 1999
    ..Results indicate that the polysulfonate Suramin inhibits both envelope protein binding, and infectivity...
  9. Denque Virus Receptor Interactions
    Rory Marks; Fiscal Year: 2002
    ..Soluble glycosaminoglycans, and the polysulfonate Suramin prevent dengue virus envelope protein binding to target cells, and prevent infection; chemically persulfated ..
  10. Suramin to Enchance Paclitaxel and Carboplatin in NSCLC
    JESSIE AU; Fiscal Year: 2002
    ..tumors induce a broad spectrum anticancer drug resistance, (b) FGF inhibitors including monoclonal antibodies and suramin completely reversed the FGF-induced resistance, (c) the suramin concentration required to reverse the FGF-induced ..
  11. FGF: A Mechanism of Acquired Multidrug Resistance
    JESSIE AU; Fiscal Year: 2005
    ..Inhibitors of FGF binding to their receptors, including monoclonal antibodies and/or suramin, completely reverse the resistance induced by exogenous FGF...
  12. PHENOTYPIC REVERSION REQUIRES LYSYL OXIDASE MRNA
    Philip Trackman; Fiscal Year: 1999
    ..show that phenotypic reversion of c-H-ras-transformed NIH3T3 cells (RS485 cells) by the anti-cancer drug suramin is accompanied by dramatically increased lysyl oxidase mRNA levels, but no increase in enzyme activity...
  13. CLINICAL TRIALS OF BIOLOGICAL RESPONSE MODIFIERS
    MICHAEL LOTZE; Fiscal Year: 1999
    ..antibody, Bec-2), and (3) active clinical and preclinical programs in testing differentiation agents such as interferon, TRA and Suramin. (4) More approaches utilizing T-cell defined tumor epitopes in constructing tumor vaccine.
  14. CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
    Mark Ratain; Fiscal Year: 2002
    ..Population pharmacology are ongoing of suramin, carboplatin, paclitaxel, 9-aminocamptothecin, 5-fluorouracil and etoposide...
  15. SEX STEROIDS AND GROWTH FACTORS IN PROSTATIC GROWTH
    Leland Chung; Fiscal Year: 1993
    ..of sex steroids and examine the GF and extracellular matrix (ECM) pathways involved in LNCaP tumor growth, using suramin and GF/ECM antibodies as tools...
  16. STEREOCHEMICAL BASIS OF ANTIAIDS AND ANTICANCER ACTIONS
    Arthur Camerman; Fiscal Year: 2000
    ..Compounds to be studied include: (1) Suramin and suramin analogues...
  17. TRIAL OF SURAMIN IN BREAST CANCER
    Joseph Aisner; Fiscal Year: 1992
    ..b>Suramin is a new antitumor compound which chemically represents a highly charged anionic polymer due to the presence of ..
  18. LOW-SHEAR 3-DIMENSIONAL IN VITRO PROSTATE TUMOR MODEL
    Robert Veltri; Fiscal Year: 1993
    ..fidelity to the in vivo tumor is established, the model will be used to assess selected chemotherapeutic agents [suramin, taxol, finasteride] to assess the utility of the model for evaluation of their therapeutic potential...
  19. MAINTENANCE AND REPAIR OF VASCULAR ENDOTHELIUM
    DENIS GOSPODAROWICZ; Fiscal Year: 1992
    ..group, including growth factors such as TGFbeta or TNFalpha, as well as unrelated molecules, such as heparin, suramin, and protamine, known to affect the angiogenic process and vascular endothelial cells proliferation...
  20. ANTI-GROWTH FACTOR THERAPY IN KAPOSI'S SARCOMA IN AIDS
    William Rom; Fiscal Year: 1990
    ..To block growth factor ligand interaction with its receptor, we will evaluate supernatants with suramin, an anti-tumor agent capable of inhibiting binding of PDGF and IGF-I to their receptors...
  21. COOPERATIVE STUDY
    Everett Vokes; Fiscal Year: 2000
    ..Sample protocols are provided for phase II trials of pyrazine diazo hydroxide or suramin in breast, colorectal, prostate, non-small cell lung and renal cancer, respectively...
  22. REGULATORS OF FIBROBLAST GROWTH FACTOR ACTIVITY
    PHILLIP ANEVSKI; Fiscal Year: 1993
    ..polysulfated carbohydrate derivatives such as pentosan polysulfate and polysulfated aromatic compounds such as suramin inhibit FGF activity and suppress the growth of cancer cells, and that heparin-like molecules are required for ..
  23. Glial Signaling:Interplay of Connexins and P2 Receptors
    Eliana Scemes; Fiscal Year: 2006
    ....
  24. PARACRINE REGULATION OF BILE DUCT SECRETION BY ATP
    JONATHAN DRANOFF; Fiscal Year: 2004
    ..The Yale School of Medicine Department of Internal Medicine has pledged that the candidate will have extensive protected research time and excellent resources for the duration of the award. ..
  25. NTPDase2 expression and function in the liver
    JONATHAN DRANOFF; Fiscal Year: 2005
    ..The experiments proposed in these specific aims will provide the basis of several new lines of liver disease research and should provide novel therapeutic targets for treatment of cholestatic and fibrotic liver disease. ..
  26. Regulation of Bile Ductular Proliferation
    JONATHAN DRANOFF; Fiscal Year: 2009
    ..We anticipate that the results of these proposed experiments will lead to novel pharmacologic approaches for the regulation of bile ductular proliferation in biliary cirrhosis. ..
  27. NABTT-Consortium Therapeutic Studies of CNS Malignancies
    Stuart Grossman; Fiscal Year: 2008
    ..abstract_text> ..
  28. Function of hair cells regenerated by Atoh1
    MARK CRUMLING; Fiscal Year: 2007
    ..This is accomplished using molecular biological, electrophysiological, and audiological techniques to probe the inner ear for hallmarks of outer hair cell structure and function. [unreadable] [unreadable] [unreadable]..
  29. 2006 Fibroblast Growth Factors in Development and Diseases
    BRADLEY OLWIN; Fiscal Year: 2006
    ..abstract_text> ..
  30. Soft Tissue Biomechanical Behavior During Acupuncture in Low Back Pain
    Helene M Langevin; Fiscal Year: 2010
    ....
  31. TRANSGLUTAMINASE PROMOTES CPPD DISEASE IN AGING JOINTS
    Ann Rosenthal; Fiscal Year: 2007
    ..These studies will contribute to our understanding of CPPD deposition disease, so that effective therapies for this common and disabling form of arthritis can be designed. ..
  32. Age-related Changes in a Myogenic Niche
    Bradley B Olwin; Fiscal Year: 2010
    ....
  33. Developmental control of cell polarity in vertebrate embryos.
    John B Wallingford; Fiscal Year: 2010
    ..Together, these experiments will help us to understand how PCP signaling influences such diverse cellular processes as convergent extension and ciliogenesis. ..
  34. MECHANISMS OF NEURONAL DEATH AND NEUROPROTECTION
    ANTHONY JOHN WINDEBANK; Fiscal Year: 2010
    ..The goal is to develop a mechanism-based therapy that will prevent the major dose-limiting side effect of the platinum compounds. ..
  35. Matrix proteins promote matrix vesicle mineralization
    Ann Rosenthal; Fiscal Year: 2007
    ..The ultimate goal of this work is to understand the pathogenesis of calcium crystal formation in articular cartilage, so that specific therapies for this disabling disease can be designed. ..
  36. ANALYSIS OF MYOGENIC GROWTH AND DIFFERENTIATION
    BRADLEY OLWIN; Fiscal Year: 2008
    ..We will test this hypothesis by identifying and isolating p38alpha/Beta-PO4 interacting partners and elucidate the cellular function of these interacting partners. ..
  37. Dissection of Ethanol Actions on Cholinergic Nerve Endings
    TIMOTHY SEARL; Fiscal Year: 2008
    ..Our preliminary data with botulinums toxins demonstrate that the synaptic vesicle protein synaptobrevin is an important target for the effects of ethanol. [unreadable] [unreadable] [unreadable] [unreadable]..
  38. Study of Intrinsic Bladder Activity by Optical Imaging
    Anthony Kanai; Fiscal Year: 2007
    ..To study the neural-chemical control of spontaneous detrusor activity; and III.) To determine the origin of detrusor overactivity in partially obstructed bladders. ..
  39. Purinergic control of medullary pain modulation
    Nathan Selden; Fiscal Year: 2006
    ..abstract_text> ..
  40. Identification of Early Markers for Ovarian Cancer
    Anna Lokshin; Fiscal Year: 2006
    ..By the end of the proposed project, we expect to construct a test based on a panel of ovarian cancer-specific antigens that has the most promising characteristics to identify women with ovarian cancer. ..
  41. CELL ADHESION IN TISSUE MORPHOGENESIS
    William Carter; Fiscal Year: 2001
    ..these results will define the molecular mechanism through which cell adhesion regulates gene expression and wound repair in epithelium. ..
  42. Phase II Trial of Tetrathiomolybdate in Prostate Cancer
    David Smith; Fiscal Year: 2002
    ..The levels of these growth factors/cytokines will then be correlated with the degree of copper depletion, PSA level and response to therapy. ..
  43. Ap4A as an Alarmone in Stress Physiology
    RICHARD HILDERMAN; Fiscal Year: 2003
    ..The information obtained in this proposal will give us insight on how to develop future proposals, biochemical and molecular experiments to determine the mechanism(s)by which Ap4A acts as an alarmone. ..
  44. FASEB Conference: Skeletal Muscle Satellite & Stem Cells
    BRADLEY OLWIN; Fiscal Year: 2003
    ....
  45. Circadian Regulation of Olfaction
    STUART DRYER; Fiscal Year: 2004
    ..abstract_text> ..
  46. HIV ENV & MACROPHAGE CHEMOKINE RECEPTOR IONIC SIGNALING
    Bruce Freedman; Fiscal Year: 2004
    ....
  47. DEVELOPMENT OF IONIC CHANNELS
    STUART DRYER; Fiscal Year: 2005
    ..Neurotrophic factors are potential therapeutic agents for neurodegeneration. This research will provide additional information on neurotrophic factor actions and interactions, especially with respect to posttranslational effects. ..
  48. INVERSE METASTATIC MODALITIES BY HEPARANASES
    Dario Marchetti; Fiscal Year: 2005
    ..They will provide a framework for the development of polysaccharide-based anti-cancer molecules as important prognostic tools and diagnostic screens for metastatic detection, diagnosis and treatment. ..
  49. Biomodulation of capecitabine by docetaxel in non-small*
    MIGUEL VILLALONA; Fiscal Year: 2005
    ..Confirmation of our working hypothesis may lead to a new treatment paradigm suitable for evaluation in the adjuvant setting. ..
  50. Communication Between Laminin 5 and Gap Junctions
    William Carter; Fiscal Year: 2005
    ..These studies will provide an understanding of components and mechanisms critical for regulating epithelial morphogenesis in development, wound repair and tumor invasion. ..
  51. Carotid Body Chemoreception: Mechanism & Development
    DAVID DONNELLY; Fiscal Year: 2006
    ..If supported, the model should lead to a pharmacologic targeting of these processes for the improved treatment of apnea and/or dyspnea. ..
  52. Biodegradable Polymer Implants for Spinal Cord Repair
    Anthony Windebank; Fiscal Year: 2006
    ..Imaging with Micro-CT and MR microscopy will be combined with histological and functional assessments to measure success in promoting regeneration. ..
  53. Genetics of Cognitive Decline Post Cancer Chemotherapy
    Tim Ahles; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  54. BIOMECHANICAL EFFECT OF ACUPUNCTURE NEEDLING
    HELENE LANGEVIN; Fiscal Year: 2001
    ..This will contribute to the fundamental understanding of acupuncture therapy and may lead to improvements in treatments. ..